Drugs / bezisterim
bezisterim
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00991107 | Sep 2009 → Aug 2010 | — | Harbor Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT00555451 | Oct 2007 → Sep 2009 | — | Harbor Therapeutics | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05083260 | Jan → Nov 2022 | Parkinson disease | BioVie Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT00712114 | Jul 2008 → Jul 2009 | rheumatoid arthritis | Harbor Therapeutics | Completed | No outcome recorded |
| Phase 1/2 | NCT00628433 | Feb 2008 → May 2009 | ulcerative colitis | Harbor Therapeutics | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT06847191 | Apr 2025 → Aug 2026 overdue | long COVID-19 | BioVie Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06757010 | Mar 2025 → May 2026 overdue | Parkinson disease | BioVie Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05970575 | Dec 2023 → Jul 2025 | traumatic brain injury | Neurological Associates of West Los Angeles | Terminated | No outcome recorded |
| Phase 2 | NCT05227820 | Jan → Jul 2022 | Alzheimer disease | Neurological Associates of West Los Angeles | Completed | No outcome recorded |
| Phase 2 | NCT00694057 | Jun 2008 → Jan 2010 | type 2 diabetes mellitus | Harbor Therapeutics | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04669028 | Aug 2021 → Sep 2023 | Alzheimer disease | BioVie Inc. | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bezisterim | “we investigated the safety and activity of bezisterim, a first-in-class, oral, blood-brain barrier-permeable, anti-inflammatory agent” PMID 40386807 ↗ May 2025 |
| Known as | 17a-ethynyl-androst-5-3b,7b,17b-triol | “This study seeks to measure changes in cognition through verbal and visual test procedures and changes in biomarkers of Alzheimer's disease and inflammatory and metabolic...” NCT05227820 ↗ |
| Known as | 17a-ethynyl-androst-5-ene-3b,7b,17b-triol | “The drug under investigation is NE3107 (17a-ethynyl-androst-5-ene-3b,7b,17b-triol).” NCT05227820 ↗ |
| Known as | 17a-ethynyl0androst-5-ene-3b, 7b, 17b-triol | “In this study, the drug under investigation is NE3107 (17a-ethynyl0androst-5-ene-3b, 7b, 17b-triol).” NCT05970575 ↗ |
| Known as | HE3286 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00555451 ↗ |
| Known as | NE3107 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05083260 ↗ |
| Known as | Triolex | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297284 ↗ |
| Action | Inhibit | “The mechanism of action for NE3107 involves selective inhibition of inflammatory mediators.” NCT05970575 ↗ |
| Modality | Small molecule | “Insulin-Sensitizing Anti-Inflammatory Small Molecule” NCT05227820 ↗ |
| Route | Oral | “When Administered Orally to Obese Adult Subjects for 28 Days” NCT00555451 ↗ |